{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:21:52Z","timestamp":1777861312655,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with locally advanced head and neck squamous cell carcinoma are receiving adjuvant radio(chemo)therapy as standard of care, according to national guidelines. However, patients with human papilloma virus (HPV) driven oropharyngeal squamous cell carcinoma (OPSCC), are shown to have superior locoregional control (LRC) rates, suggesting that they are likely being overtreated. To date it is unknown, if and to which extent adjuvant radiotherapy can be safely reduced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design<\/jats:title>\n                    <jats:p>The interventional multicentric DELPHI trial is investigating step-wise radiation dose reduction in patients with both p16-overexpressing and HPV16 DNA positive OPSCC. Depending on international clinical and histopathological risk factors, patients are being enrolled in the high-risk or intermediate-risk arm. Patients of the high-risk arm are receiving standard simultaneous chemotherapy with cisplatin. Patients with smoking history of at least 30 packyears are being treated in the observational arm.<\/jats:p>\n                    <jats:p>Primary endpoint of the DELPHI trial is LRC after 24 months. Secondary endpoints are acute and late toxicity, quality of life during and up to 24 months after the end of therapy as well as LRC and overall survival after 60 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Primary aim of the DELPHI trial is to show that radiation dose reduction is safe and therefore feasible in patients with HPV-positive OPSCC. Secondary objective is to show that radiation-dose reduction leads to less late toxicity compared with standard treatment and thus improves quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The DELPHI trial is registered at clinicaltrials.gov under the identifier NCT03396718.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16050-x","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:04:18Z","timestamp":1777467858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["De-escalation of adjuvant radio(chemo)therapy for patients with HPV-positive head and neck squamous cell carcinoma: study protocol for a phase I trial to reduce late toxicity (DELPHI)"],"prefix":"10.1186","volume":"26","author":[{"given":"Annett","family":"Linge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Lohaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Appold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther G.C.","family":"Troost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susann","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"L\u00f6ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mechthild","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"16050_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0360-3016(93)90167-T","volume":"26","author":"LJ Peters","year":"1993","unstructured":"Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26:3\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0360-3016(01)01690-X","volume":"51","author":"KK Ang","year":"2001","unstructured":"Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR3","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.05.0906","volume":"24","author":"J Bernier","year":"2006","unstructured":"Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol. 2006;24:2629\u201335.","journal-title":"J Clin Oncol"},{"key":"16050_CR4","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","volume":"84","author":"JS Cooper","year":"2012","unstructured":"Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84:1198\u2013205.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR5","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.ijrobp.2009.06.090","volume":"76","author":"JO Deasy","year":"2010","unstructured":"Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76:S58\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR6","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.ijrobp.2009.03.079","volume":"76","author":"T Rancati","year":"2010","unstructured":"Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, et al. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys. 2010;76:S64\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","volume":"26","author":"AK Chaturvedi","year":"2008","unstructured":"Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612\u20139.","journal-title":"J Clin Oncol"},{"key":"16050_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ejca.2014.12.018","volume":"51","author":"I Tinhofer","year":"2015","unstructured":"Tinhofer I, J\u00f6hrens K, Keilholz U, Kaufmann A, Lehmann A, Weichert W, et al. Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. Eur J Cancer. 2015;51:514\u201321.","journal-title":"Eur J Cancer"},{"key":"16050_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.semradonc.2011.12.004","volume":"22","author":"KK Ang","year":"2012","unstructured":"Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012;22:128\u201342.","journal-title":"Semin Radiat Oncol"},{"key":"16050_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djn011","volume":"100","author":"C Fakhry","year":"2008","unstructured":"Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"16050_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.radonc.2010.04.022","volume":"95","author":"P Lassen","year":"2010","unstructured":"Lassen P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol. 2010;95:371\u201380.","journal-title":"Radiother Oncol"},{"key":"16050_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2009.10.008","volume":"94","author":"P Lassen","year":"2010","unstructured":"Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 2010;94:30\u20135.","journal-title":"Radiother Oncol"},{"key":"16050_CR13","doi-asserted-by":"crossref","unstructured":"Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhoi BP, Overgaard M et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011;100:49-55.","DOI":"10.1016\/j.radonc.2011.02.010"},{"key":"16050_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.radonc.2013.08.036","volume":"108","author":"P Lassen","year":"2013","unstructured":"Lassen P, Overgaard J, Eriksen JG. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. Radiother Oncol. 2013;108:489\u201394.","journal-title":"Radiother Oncol"},{"key":"16050_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.radonc.2014.11.011","volume":"113","author":"F Lohaus","year":"2014","unstructured":"Lohaus F, Linge A, Tinhofer I, Budach V, Gkika E, Stuschke M, et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2014;113:317\u201323.","journal-title":"Radiother Oncol"},{"key":"16050_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393:51\u201360.","journal-title":"Lancet"},{"key":"16050_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40\u201350.","journal-title":"Lancet"},{"key":"16050_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","volume":"40","author":"RL Ferris","year":"2022","unstructured":"Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et al. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16\u2009+\u2009Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40:138\u201349.","journal-title":"J Clin Oncol"},{"key":"16050_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","volume":"106","author":"S Swisher-McClure","year":"2020","unstructured":"Swisher-McClure S, Lukens JN, Aggarwal C, Ahn P, Basu D, Bauml JM, et al. A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx. Int J Radiat Oncol Biol Phys. 2020;106:725\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR20","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.19.00463","volume":"37","author":"DJ Ma","year":"2019","unstructured":"Ma DJ, Price KA, Moore EJ, Patel SH, Hinni ML, Garcia JJ, et al. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. J Clin Oncol. 2019;37:1909\u201318.","journal-title":"J Clin Oncol"},{"key":"16050_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S1470-2045(25)00324-9","volume":"26","author":"D Ma","year":"2025","unstructured":"Ma D, Price K, Moore E, Patel S, Hinni M, Routman D, et al. De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2025;26:1227\u201339.","journal-title":"Lancet Oncol"},{"key":"16050_CR22","doi-asserted-by":"crossref","unstructured":"R\u00fchle A, Grosu AL, Nicolay NH. De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers-HPV and Beyond. Cancers (Basel). 2021;13 (9):2204.","DOI":"10.3390\/cancers13092204"},{"key":"16050_CR23","doi-asserted-by":"publisher","first-page":"107089","DOI":"10.1016\/j.oraloncology.2024.107089","volume":"159","author":"J Morgenthaler","year":"2024","unstructured":"Morgenthaler J, Trommer M, Khor R, Wada M, Bahig H, Garden AS, et al. Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches. Oral Oncol. 2024;159:107089.","journal-title":"Oral Oncol"},{"key":"16050_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"},{"key":"16050_CR25","doi-asserted-by":"publisher","first-page":"71761","DOI":"10.18632\/oncotarget.12335","volume":"7","author":"CG Larsen","year":"2016","unstructured":"Larsen CG, Jensen DH, Carlander AF, Kiss K, Andersen L, Olsen CH, et al. Novel nomograms for survival and progression in HPV\u2009+\u2009and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients. Oncotarget. 2016;7:71761\u201372.","journal-title":"Oncotarget"},{"key":"16050_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.radonc.2014.09.005","volume":"113","author":"E Rios Velazquez","year":"2014","unstructured":"Rios Velazquez E, Hoebers F, Aerts HJ, Rietbergen MM, Brakenhoff RH, Leemans RC, et al. Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiother Oncol. 2014;113:324\u201330.","journal-title":"Radiother Oncol"},{"key":"16050_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.oraloncology.2014.02.001","volume":"50","author":"JM Vainshtein","year":"2014","unstructured":"Vainshtein JM, Spector ME, McHugh JB, Wong KK, Walline HM, Byrd SA, et al. Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2014;50:513\u20139.","journal-title":"Oral Oncol"},{"key":"16050_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.radonc.2017.12.007","volume":"127","author":"A Linge","year":"2018","unstructured":"Linge A, Sch\u00f6tz U, L\u00f6ck S, Lohaus F, von Neubeck C, Gudziol V, et al. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiother Oncol. 2018;127:27\u201335.","journal-title":"Radiother Oncol"},{"key":"16050_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"16050_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.radonc.2014.10.001","volume":"113","author":"T Skripcak","year":"2014","unstructured":"Skripcak T, Belka C, Bosch W, Brink C, Brunner T, Budach V, et al. Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. Radiother Oncol. 2014;113:303\u20139.","journal-title":"Radiother Oncol"},{"key":"16050_CR31","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1109\/JBHI.2015.2450833","volume":"20","author":"T Skripcak","year":"2016","unstructured":"Skripcak T, Just U, Simon M, B\u00fcttner D, L\u00fchr A, Baumann M. Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. EEE J Biomedical Health Inf. 2016;20:1397\u2013403.","journal-title":"EEE J Biomedical Health Inf"},{"key":"16050_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.radonc.2006.03.009","volume":"79","author":"V Gregoire","year":"2006","unstructured":"Gregoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006;79:15\u201320.","journal-title":"Radiother Oncol"},{"key":"16050_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","volume":"110","author":"V Gregoire","year":"2014","unstructured":"Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014;110:172\u201381.","journal-title":"Radiother Oncol"},{"key":"16050_CR34","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","volume":"76","author":"JP Kirkpatrick","year":"2010","unstructured":"Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010;76:S42\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR35","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.ijrobp.2009.08.078","volume":"76","author":"C Mayo","year":"2010","unstructured":"Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys. 2010;76:S36\u201341.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16050_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","volume":"64","author":"SJ Pocock","year":"1977","unstructured":"Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64:191\u20139.","journal-title":"Biometrika"},{"key":"16050_CR37","doi-asserted-by":"publisher","DOI":"10.1201\/9780367805326","volume-title":"Group Sequential Methods with Applications to Clinical Trials","author":"C Jennison","year":"1999","unstructured":"Jennison C, Tumbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman&Hall\/CRC; 1999."},{"key":"16050_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","volume":"61","author":"A Ivanova","year":"2005","unstructured":"Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005;61:540\u20135.","journal-title":"Biometrics"},{"key":"16050_CR39","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1158\/1078-0432.CCR-15-1990","volume":"22","author":"A Linge","year":"2016","unstructured":"Linge A, L\u00f6ck S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, et al. Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clin Cancer Res. 2016;22:2639\u201349.","journal-title":"Clin Cancer Res"},{"key":"16050_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.radonc.2016.11.008","volume":"121","author":"A Linge","year":"2016","unstructured":"Linge A, Lohaus F, L\u00f6ck S, Nowak A, Gudziol V, Valentini C, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2016;121:364\u201373.","journal-title":"Radiother Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16050-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:40:22Z","timestamp":1777520422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16050"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16050-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent of the study protocol was obtained from the expert committee of the German Society for Radiation Oncology (DEGRO). The study was approved by the leading Ethics Committee at the TUD Dresden University of Technology (EK257062017) and local ethical approval is necessary of every partner center before the initiation of their center. Written informed consent is obtained from every participant prior to study inclusion by qualified investigators at the participating centres. Participants will be informed about the purpose, procedures, potential risks and benefits of the study in accordance with ethical and regulatory requirements. Standardised consent forms, approved by the ethics committees, are used. Model informed consent forms are available from the corresponding author upon reasonable request. All patient data are pseudonymised prior to analysis. Access to identifiable data is restricted to authorised study personnel. The study is being monitored regularly. Important protocol modifications (e.g. changes to eligibility criteria, outcomes or analyses) will be communicated to the responsible ethics committees, participating study centres, and trial registries in accordance with regulatory requirements. The trial registry entry will be updated accordingly. Where applicable, trial participants will be informed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michael Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and\/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards and boards of trustees. Michael Baumann confirms that he has no conflict of interest with respect to this paper. In the past 5 years, Mechthild Krause, Annett Linge and Esther G.C. Troost were involved in a publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan (2019-2022), Attomol GmbH (2019-2022), GA Generic Assays GmbH (2019-2022), Gesellschaft f\u00fcr medizinische und wissenschaftliche genetische Analysen (2019-2022), Lipotype GmbH (2019-2022) and PolyAn GmbH (2019-2022). Mechthild Krause, Annett Linge and Esther G.C. Troost confirm that, to the best of their knowledge, none of the above-mentioned funding sources were involved in the preparation of this paper. Amir Abdollahi received third-party funding from the National Institutes of Health (NIH) and the German Research Foundation (DFG). In addition, he received grants or other support from, or served on scientific advisory boards (SAB) at Merck KGaA, Merck Serono, Bayer, Bristol Myers Squibb (BMS), FibroGen Inc., Roche, and BioMedX (within the past 5 years and ongoing). Amir Abdollahi declares that none of the above-mentioned funding sources were involved in the preparation of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"542"}}